0.8436

8.88% 0.0688

Pre-market: .91 0.0664 +7.87%

Rein Therapeutics Inc (RNTX)

Overview News Price History Discussions Forecast

Rein Therapeutics Inc stock is traded at $0.8436, with a volume of 567.99K. It is up +8.88% in the last 24 hours and up +13.16% over the past month. Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Previous Close:

$0.7748

Open:

$0.79

24h Volume:

567.99K

Relative Volume:

1.09

Market Cap:

$72.77M

Revenue:

Net Income/Loss:

$-50.21M

P/E Ratio:

-0.4428

EPS:

-1.9053

Net Cash Flow:

$-16.61M

1W Performance:

+7.77%

1M Performance:

+13.16%

6M Performance:

-26.64%

1Y Performance:

-33.05%

1-Day Range:

$0.79

$0.87

1-Week Range:

$0.7293

$0.87

52-Week Range:

$0.694

$2.18

Rein Therapeutics Inc Stock (RNTX) Company Profile

Name

Rein Therapeutics Inc

Sector

Healthcare (1075)

Industry

Biotechnology (600)

Phone

(737) 802-1989

Address

12407 N. MOPAC EXPY., AUSTIN

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

RNTX's Discussions on Twitter

Compare RNTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNTX Rein Therapeutics Inc	0.8436	68.46M	0	-50.21M	-16.61M	-1.9053
VRTX Vertex Pharmaceuticals Inc	557.96	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	843.47	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,053.46	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	148.87	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.87	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-22-25	Initiated	H.C. Wainwright	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-24-17	Initiated	BofA/Merrill	Buy
Jul-24-17	Initiated	Jefferies	Buy
Jul-24-17	Initiated	William Blair	Outperform

Rein Therapeutics Inc Stock (RNTX) Latest News

Aug 20, 2026

Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - kalkine.ca

Aug 20, 2026

Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn

Aug 20, 2026

Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Australia

Aug 20, 2026

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times

Aug 20, 2026

Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative

Aug 20, 2026

Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView

Aug 20, 2026

FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan

Aug 20, 2026

Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat

Aug 20, 2026

Aug 19, 2026

What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat

Aug 19, 2026

Aug 18, 2026

RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus

Aug 18, 2026

Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat

Aug 18, 2026

H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada

Aug 18, 2026

Aug 15, 2026

RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - Vinanet

Aug 15, 2026

Aug 14, 2026

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat

Aug 14, 2026

Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - Vinanet

Aug 14, 2026

Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart

Aug 14, 2026

Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Aug 14, 2026

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Aug 14, 2026

Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative

Aug 14, 2026

Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo

Aug 14, 2026

Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView

Aug 14, 2026

RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView

Aug 14, 2026

Rein Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Aug 14, 2026

Aug 13, 2026

RNTX Q1 2026 Earnings: Narrowed Per-Share Loss Beats Consensus by Nearly 62%Financial Health Score - vinanet.vn

Aug 13, 2026

Aug 11, 2026

RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Improved Capital DisciplineOne-Time Loss Impact - vinanet.vn

Aug 11, 2026

Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9%Here's Why - MarketBeat

Aug 11, 2026

Aug 10, 2026

Rein Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView

Aug 10, 2026